Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Broker Meets Biotech, Perth (March 2016)
21 slides from Pyc Therapeutics's conference presentation, Apr 1, 2016
Slide 1: Phylogica 2016 Broker Meets Biotech
For personal use only Phylogica 2016 Broker Meets Biotech (PYC:ASX) Developing new drugs against intracellular cancer targets beyond the reach of existing therapies
Slide 2: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) For personal use only [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: Phylogica's exciting transformation
Phylogica’s exciting transformation: For personal use only From: A platform company using its proprietary Phylomer technology for drug discovery To: An cancer-focussed company using its disruptive technology to develop novel drugs against intracellular targets that are beyond the reach of existing t
Slide 4: 2015 Highlights
For personal use only 2015 Highlights § Completed $10m capital raise in July, 2015 § Validated Phylomers for ‘best-in-class’ ability to deliver large drugs (biologics) inside cancer cells and to hit ‘undruggable’ cancer targets § Advanced in-house pipeline towards clinic focussed on blood cancers §
Slide 5: Corporate Snapshot
For personal use only Corporate Snapshot Shareholders % Summary B. Hockings 28 ASX PYC Cash (Dec/15) $9.7m Sietsma Holdings 9 Net Burn $2.9m Swift 5 Market Cap $28m Top 15 56 Shares on issue ~2,000m Executive Team Dr Richard Hopkins – CEO Dr Paul Watt - CSO Board of Directors B. McHarrie Dr D. Wilso
Slide 6: Core Technology
For personal use only Core Technology
Slide 7: Majority of drug targets (80%) are inside cells
Majority of drug targets (80%) are inside cells For personal use only Distribution of drug targets Small Molecules Cell Membrane Outside Cells Inside Cells Biologics (20%) (80%) (Smart drugs) (10%) Market for biologics drugs $220b $0 § PYC addressing unmet need to deliver biologic drugs inside cells
Slide 8: Cell Penetrating Phylomer peptides for delivering biologics cargoes inside cells
Cell Penetrating Phylomer peptides for delivering biologics cargoes inside cells 1 For personal use only 2 3 Potential to expand the druggable intracellular landscape by >10-fold Broker Meets Biotech, Perth (March 2016) 8
Slide 9: Using cell penetrating Phylomer drugs to hit MYC
For personal use only Using cell penetrating Phylomer drugs to hit MYC – an ‘undruggable’ intracellular cancer target
Slide 10: MYC: A classic cancer target
MYC: A classic cancer target § MYC: Is ‘activated’ in most human cancers (>50%) –recognised as a key driver of disease for > 40years For personal use only Proliferation MYC Cell Growth Metabolism § Myc is found inside cells. Considered undruggable with normal therapies. § Treating MYC can eradicate
Slide 11: Phylomer CPP-Omomyc fusions are potent!
Phylomer CPP-Omomyc fusions are potent! § Kills different types of cancer cells with unprecedented For personal use only potencies § Improves efficacy of other cancer drugs up to 10X. § CPP-Omomyc fusion significantly reduced tumor size in an animal model of breast cancer. § Identified Phylomers tha
Slide 12: Drug development focus transforms disruptive platform
Drug development focus transforms disruptive platform For personal use only Drug Development Drug Candidates Cell penetrating Phylomers smart Disruptive Hits Phylomers drugs Technology Drug Delivery Solution + Drug Discovery Engine Higher value commercial returns Broker Meets Biotech, Perth (March 2
Slide 13: Phylogica's Proprietary Cancer Pipeline
For personal use only Phylogica’s Proprietary Cancer Pipeline
Slide 14: Phylogica's Pipeline focussed on blood cancers
Phylogica’s Pipeline focussed on blood cancers § Confirmed ability to address unmet need and establish fast and efficient For personal use only path to clinical trial § Blood cancers considered easier to access than solid tumours. Program Target Indications Hit Discovery Hit to Lead Validation Precl
Slide 15: Key phases to clinical development
For personal use only Key phases to clinical development Hit Identification Hit to Lead Lead Candidates Lead Candidate (3 Targets) (1-2 Targets) (1-2) Discovery Validation in Animal Models of Cancer Lead Optimisation Preclinical/IND 2015 2016 2017 Broker Meets Biotech, Perth (March 2016) 15
Slide 16: Preclinical phase offers significant commercial returns
For personal use only Preclinical phase offers significant commercial returns
Slide 17: Preclinical deals: continuing trend to higher values
Preclinical deals: continuing trend to higher values For personal use only § Significant trend towards preclinical licensing as pharma looks to replenish dwindling pipelines (focus on discovery engines) § > 50% of top value licensing deals in 2013 & 2014 involved preclinical/discovery assets § Media
Slide 18: Essential requirements for preclinical deals
Essential requirements for preclinical deals For personal use only Feature PYC Platform addresses unique target landscape and unmet medical need. Strong IP barriers and Freedom to Operate (FTO) Well supported biological rationale for target Differentiated product/disruptive technology – ‘first-in-cl
Slide 19: Summary
Summary § Disruptive Phylomer technology offering integrated drug delivery and For personal use only discovery solutions § Advancing proprietary pipeline of novel ‘best-in-class’ drugs against challenging intracellular cancer targets (MYC) § Immediate focus on validating candidate drugs in animal mo
Slide 20: Thankyou!
For personal use only Thankyou! Broker Meets Biotech, Perth (March 2016) 20
Slide 21: Contact Details
Dr. Richard Hopkins Contact Details Dr. Paul Watt Chief Executive Officer Chief Scientific Officer Tel: +61 8 9489 7777 Tel: +61 8 9489 7777 Fax: +61 8 9489 7700 For personal use only Fax: +61 8 9489 7700 Mobile: +61 405 656 868 Mobile: +61 421 550 213 richardh@phylogica.com paulw@phylogica.com www.